International, Multi-center, Double Blind 9-month Follow-up Extension Study Assessing the Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

Trial Profile

International, Multi-center, Double Blind 9-month Follow-up Extension Study Assessing the Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Baclofen/naltrexone/sorbitol (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Adverse reactions
  • Acronyms PLEO-CMT-FU
  • Sponsors Pharnext
  • Most Recent Events

    • 22 Mar 2017 New source identified and integrated (European Clinical Trials Database; EudraCT2015-002379-81)
    • 16 Mar 2017 According to a Pharnext media release, top-line results are expected in the second quarter of 2019.
    • 06 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top